English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT). These findings may inform decisions on the clinical level as well as policy decisions. The analysis is published in Annals of Internal Medicine.
Tag: DOAC
Two Blood Thinners at Once: More Risk with the Same Reward
For some patients, adding aspirin to a direct oral anticoagulant is an equation that rarely adds up.
Instrumentation Laboratory Receives US FDA Marketing Authorization for the First Apixaban Diagnostic Test
Instrumentation Laboratory Receives US FDA Marketing Authorization for the First Apixaban Diagnostic Test